Compare EQBK & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQBK | PHAT |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 989.1M | 894.0M |
| IPO Year | 2015 | 2019 |
| Metric | EQBK | PHAT |
|---|---|---|
| Price | $47.30 | $10.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $51.33 | $19.83 |
| AVG Volume (30 Days) | 83.6K | ★ 1.0M |
| Earning Date | 04-14-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $74.58 | $93.04 |
| Revenue Next Year | $5.11 | $58.91 |
| P/E Ratio | $58.64 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $36.04 | $7.61 |
| 52 Week High | $50.07 | $18.31 |
| Indicator | EQBK | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.79 | 52.16 |
| Support Level | $44.45 | $10.92 |
| Resistance Level | $48.58 | $12.99 |
| Average True Range (ATR) | 0.95 | 0.58 |
| MACD | -0.04 | 0.16 |
| Stochastic Oscillator | 59.47 | 75.39 |
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.